{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:43:47Z","timestamp":1776951827726,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The S\u00e3o Paulo Research Foundation","award":["2013\/13295-9"],"award-info":[{"award-number":["2013\/13295-9"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14622-x","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T20:42:36Z","timestamp":1754167356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion"],"prefix":"10.1186","volume":"25","author":[{"given":"Carlos Sergio Rocha","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisete Ribeiro","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina Rocha","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Figueiredo Braga Colares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa Adelia","family":"Alvarenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta Karla Barbosa","family":"Sales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda Cabral","family":"Roque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evaldo","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronei Luciano","family":"Mamoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena Marques","family":"Pagliarelli Acencio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"14622_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/resp.12496","volume":"20","author":"JM Porcel","year":"2015","unstructured":"Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015;20:654\u20139.","journal-title":"Respirology"},{"key":"14622_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12931-024-02684-7","volume":"25","author":"F Gonnelli","year":"2024","unstructured":"Gonnelli F, Hassan W, Bonifazi M, Pinelli V, Bedawi EO, Porcel JM, et al. Malignant pleural effuison: current Understanding and therapeutic approach. Respir Res. 2024;25:47.","journal-title":"Respir Res"},{"key":"14622_CR3","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/annonc\/mdu089","volume":"25","author":"J Vansteenkiste","year":"2014","unstructured":"Vansteenkiste J, Crin\u00f2 L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, et al. 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;25:1462\u201374.","journal-title":"Ann Oncol"},{"key":"14622_CR4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1590\/1809-4503201400040017","volume":"17","author":"LH Araujo","year":"2014","unstructured":"Araujo LH, Baldotto CS, Zukin M, Vieira FM, Victorino AP, Rocha VR, et al. Survival and prognostic factors in patients with non-small cell lung cancer treated in private health care. Rev Bras Epidemiol. 2014;17:1001\u201314.","journal-title":"Rev Bras Epidemiol"},{"key":"14622_CR5","first-page":"279","volume":"8","author":"D Zhang","year":"2014","unstructured":"Zhang D, Yang R, Wang S, Dong Z. Paclitaxel: new uses for an old drug. Drug Des Devel Ther. 2014;8:279\u201384.","journal-title":"Drug Des Devel Ther"},{"key":"14622_CR6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/biomedicines9050500","volume":"9","author":"HM Nawara","year":"2021","unstructured":"Nawara HM, Afify SM, Hassan G, Zahra MH, Seno A, Seno M. Paclitaxel-based chemotherapy targeting cancer stem cells from mono- to combination therapy. Biomedicines. 2021;9:500.","journal-title":"Biomedicines"},{"key":"14622_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/WHE.10.42","volume":"6","author":"P Vishnu","year":"2010","unstructured":"Vishnu P, Roy V. Nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer. Womens Health (Lond). 2010;6:495\u2013506.","journal-title":"Womens Health (Lond)"},{"key":"14622_CR8","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.2147\/DDDT.S88023","volume":"9","author":"MN Kundranda","year":"2015","unstructured":"Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther. 2015;9:3767\u201377.","journal-title":"Drug Des Devel Ther"},{"key":"14622_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/21691401.2018.1552595","volume":"47","author":"H Tan","year":"2019","unstructured":"Tan H, Hu J, Liu S. Efficacy and safety of nanoparticle albumin-bound Paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis. Artif Cells Nanomed Biotechnol. 2019;47:268\u201377.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"14622_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113543","volume":"9","author":"RA de Mello","year":"2020","unstructured":"de Mello RA, Neves NM, Tadokoro H, Amaral GA, Castelo-Branco P, Zia VAA. New target therapies in advanced non-small cell lung cancer: a review of the literature and future perspectives. J Clin Med. 2020;9: 3543.","journal-title":"J Clin Med"},{"key":"14622_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00432-020-03129-6","volume":"146","author":"H Qiang","year":"2020","unstructured":"Qiang H, Chang Q, Xu J, Qian J, Zhang Y, Lei Y, et al. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2020;146:631\u201345.","journal-title":"J Cancer Res Clin Oncol"},{"key":"14622_CR12","doi-asserted-by":"publisher","first-page":"105093","DOI":"10.18632\/oncotarget.21362","volume":"8","author":"MMP Acencio","year":"2017","unstructured":"Acencio MMP, Puka J, Alvarenga VA, Martins V, de Carvalho MLP, Marchi E, et al. Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion. Oncotarget. 2017;8:105093\u2013102.","journal-title":"Oncotarget"},{"key":"14622_CR13","doi-asserted-by":"publisher","first-page":"e75287","DOI":"10.1371\/journal.pone.0075287","volume":"8","author":"HH Yeh","year":"2013","unstructured":"Yeh HH, Chang WT, Lu KC, Lai WW, Liu HS, Su WC. Upregulation of tissue factor by activated Stat3 contributes to malignant pleural effusion generation via enhancing tumor metastasis and vascular permeability in lung adenocarcinoma. PLoS One. 2013;8:e75287.","journal-title":"PLoS One"},{"key":"14622_CR14","doi-asserted-by":"publisher","first-page":"e3996","DOI":"10.1097\/MD.0000000000003996","volume":"95","author":"A Verma","year":"2016","unstructured":"Verma A, Phua CK, Sim WY, Algoso RE, Tee KS, Lew SJ, et al. Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion. Med (Baltim). 2016;95:e3996.","journal-title":"Med (Baltim)"},{"key":"14622_CR15","first-page":"224","volume":"45","author":"N Hayama","year":"2020","unstructured":"Hayama N, Hattori S, Takahashi G, Takahashi F, Takeuchi T, Tanaka J, et al. Cytokine\/Chemokine\/Growth factor levels in malignant pleural effusion of Non-small cell lung Cancer. Tokai J Exp Clin Med. 2020;45:224\u20139.","journal-title":"Tokai J Exp Clin Med"},{"key":"14622_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0662-2","volume":"13","author":"MM Acencio","year":"2015","unstructured":"Acencio MM, Puka J, Marchi E, Antonangelo L, Terra RM, Vargas FS, et al. A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells. J Transl Med. 2015;13: 302.","journal-title":"J Transl Med"},{"key":"14622_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.arbres.2013.11.007","volume":"50","author":"JM Porcel","year":"2014","unstructured":"Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol. 2014;50:161\u20135.","journal-title":"Arch Bronconeumol"},{"key":"14622_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"15","author":"N Ferrara","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385\u2013403.","journal-title":"Nat Rev Drug Discov"},{"key":"14622_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.143068","volume":"310","author":"S Abbaspour","year":"2025","unstructured":"Abbaspour S, Mohamadzadeh M, Shojaosadati SA. Protein-based nanocarriers for Paclitaxel (PTX) delivery in cancer treatment: a review. Int J Biol Macromol. 2025;310: 143068.","journal-title":"Int J Biol Macromol"},{"key":"14622_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12931-025-03263-0","volume":"26","author":"Q Cheng","year":"2025","unstructured":"Cheng Q, Zuo X, Wang Z, Lu W, Jiang Y, Liu J, Li X, Xu Q, Zhu S, Liu X, Song Y, Zhan P, Lv T. Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion. Respir Res. 2025;26:180.","journal-title":"Respir Res"},{"key":"14622_CR21","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.2147\/IJN.S321416","volume":"16","author":"L Tang","year":"2021","unstructured":"Tang L, Mei Y, Shen Y, He S, Xiao Q, Yin Y, Xu Y, Shao J, Wang W, Cai Z. Nanoparticle-Mediated targeted drug delivery to remodel tumor microenvironment for Cancer therapy. Int J Nanomed. 2021;16:5811\u201329.","journal-title":"Int J Nanomed"},{"key":"14622_CR22","doi-asserted-by":"publisher","DOI":"10.1590\/1518-8345.0564.2688","volume":"24","author":"NO Sawada","year":"2016","unstructured":"Sawada NO, Nicolussi AC, de Paula JM, Garcia-Caro MP, Marti-Garcia C, Cruz-Quintana F. Quality of life of Brazilian and Spanish cancer patients undergoing chemotherapy: an integrative literature review. Rev Lat-Am Enfermagem. 2016;24: e2688.","journal-title":"Rev Lat-Am Enfermagem"},{"key":"14622_CR23","doi-asserted-by":"publisher","first-page":"103821","DOI":"10.1016\/j.breast.2024.103821","volume":"78","author":"M Schmidt","year":"2024","unstructured":"Schmidt M, Loibl S. Chemotherapy in older patients with early breast cancer. Breast. 2024;78:103821.","journal-title":"Breast"},{"key":"14622_CR24","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1517\/14656566.9.15.2603","volume":"9","author":"E Saloustros","year":"2008","unstructured":"Saloustros E, Mavroudis D, Georgoulias V. Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother. 2008;9:2603\u201316.","journal-title":"Expert Opin Pharmacother"},{"key":"14622_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0954-6111(98)90294-3","volume":"92","author":"RP Perng","year":"1998","unstructured":"Perng RP, Chen YM, Wu MF, Chou KC, Lin WC, Liu JM, et al. Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions. Respir Med. 1998;92:473\u20139.","journal-title":"Respir Med"},{"key":"14622_CR26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00280-011-1765-y","volume":"69","author":"G Lombardi","year":"2012","unstructured":"Lombardi G, Nicoletto MO, Gusella M, Fiduccia P, Dalla Palma M, Zuin A, et al. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. Cancer Chemother Pharmacol. 2012;69:781\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"key":"14622_CR27","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","volume":"7","author":"WJ Gradishar","year":"2006","unstructured":"Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7:1041\u201353.","journal-title":"Expert Opin Pharmacother"},{"key":"14622_CR28","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794\u2013803.","journal-title":"J Clin Oncol"},{"key":"14622_CR29","doi-asserted-by":"publisher","first-page":"6421","DOI":"10.7150\/jca.47072","volume":"11","author":"X Hao","year":"2020","unstructured":"Hao X, Zhu Y, Mu Y, Wang S, Li J, Xing P. Nab-paclitaxel in combination with bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen. J Cancer. 2020;11:6421\u20138.","journal-title":"J Cancer"},{"key":"14622_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-3-030-35727-6_2","volume":"1225","author":"R Yamaguchi","year":"2020","unstructured":"Yamaguchi R, Perkins G. An emerging model for cancer development from a tumor microenvironment perspective in mice and humans. Adv Exp Med Biol. 2020;1225:19\u201329.","journal-title":"Adv Exp Med Biol"},{"key":"14622_CR31","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1158\/0008-5472.CAN-11-4094","volume":"72","author":"SP Kerkar","year":"2012","unstructured":"Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012;72:3125\u201330.","journal-title":"Cancer Res"},{"key":"14622_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2021","unstructured":"Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33:127\u201348.","journal-title":"Int Immunol"},{"key":"14622_CR33","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","volume":"37","author":"N Kumari","year":"2016","unstructured":"Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37:11553\u201372.","journal-title":"Tumour Biol"},{"key":"14622_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"14622_CR35","doi-asserted-by":"publisher","first-page":"e0181125","DOI":"10.1371\/journal.pone.0181125","volume":"12","author":"EM Silva","year":"2017","unstructured":"Silva EM, Mariano VS, Pastrez PRA, Pinto MC, Castro AG, Syrjanen KJ, Longatto-Filho A. High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer. PLoS One. 2017;12:e0181125.","journal-title":"PLoS One"},{"key":"14622_CR36","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1096\/fj.13-240580","volume":"28","author":"MJ Puppa","year":"2014","unstructured":"Puppa MJ, Gao S, Narsale AA, Carson JA. Skeletal muscle glycoprotein 130\u2019s role in Lewis lung carcinoma-induced cachexia. FASEB J. 2014;28:998\u20131009.","journal-title":"FASEB J"},{"key":"14622_CR37","doi-asserted-by":"publisher","first-page":"e007310","DOI":"10.1136\/jitc-2023-007310","volume":"11","author":"AR Naqash","year":"2023","unstructured":"Naqash AR, McCallen JD, Mi E, Iivanainen S, Marie MA, Gramenitskaya D, Clark J, Koivunen JP, Macherla S, Jonnalagadda S, Polsani S, Jiwani RA, Hafiz M, Muzaffar M, Brunetti L, Stroud CRG, Walker PR, Wang K, Chung Y, Ruppin E, Lee SH, Yang LV, Pinato DJ, Lee JS, Cortellini A. Increased interleukin-6\/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. J Immunother Cancer. 2023;11:e007310.","journal-title":"J Immunother Cancer"},{"key":"14622_CR38","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4414\/smw.2009.12584","volume":"139","author":"P Schuetz","year":"2009","unstructured":"Schuetz P, Christ-Crain M, M\u00fcller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections\u2013hope for hype? Swiss Med Wkly. 2009;139:318\u201326.","journal-title":"Swiss Med Wkly"},{"key":"14622_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5858\/arpa.2021-0418-OA","volume":"147","author":"LM Nova-Camacho","year":"2023","unstructured":"Nova-Camacho LM, Gomez-Dorronsoro M, Guarch R, Cordoba A, Cevallos MI, Panizo-Santos A. Cardiac metastasis from solid cancers: a 35-year single-center autopsy study. Arch Pathol Lab Med. 2023;147:177\u201384.","journal-title":"Arch Pathol Lab Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14622-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14622-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14622-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:42:51Z","timestamp":1757335371000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14622-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14622"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14622-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5389405\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The methods and experimental procedures were approved by the Animal Use Ethics Committee by Faculdade de Medicina da Universidade de S\u00e3o Paulo (CEUA 1216\/2019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1261"}}